A Trial of -Lopinavir-Ritonavir (Kaletra) https
Post# of 148185
https://www.nejm.org/doi/full/10.1056/NEJMoa2001282
CONCLUSIONS
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308. opens in new tab.)
Other Info
https://www.fiercepharma.com/pharma-asia/does...tudy-finds